ArticleFrontiers in medicine2026
From static guidelines to dynamic personalization: a novel AI-driven evidence-based paradigm for low-concentration atropine prescribing in myopia control.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The rapid increase in the global incidence of myopia poses challenges for prevention and management. Evidence-based low-concentration atropine eye drops can effectively slow down the progression of myopia. However the massive and constantly updated research data place a burden on clinicians, especially in primary care or regions with limited resources, hindering knowledge integration and evidence-based decision-making. There is still a gap in patients' access to reliable and personalized guidance. To address this issue, we developed MyoATP-AI-powered evidence based decision support system specifically designed for low-concentration atropine myopia control, built upon a GraphRAG and chain-of-thought reasoning architecture. Methods: We systematically searched PubMed (2000-2025) for literature on "atropine, myopia", screening 104 relevant clinical articles and constructing a specialized dataset. Based on this, we developed MyoATP-AI, an AI-assisted diagnostic system combining GraphRAG and chain-of-thought reasoning. The knowledge graph structure was optimized through community detection and graph embedding. System performance was evaluated using the BLEU, ROUGE, and RAGAS frameworks. Five ophthalmologists rated the system's safety, professionalism, fluency, comprehensiveness, and satisfaction. Finally, we compared the 2024 consensus opinion with MyoATP-AI. Results: MyoATP-AI demonstrated excellent performance in fidelity, relevance, and context recall. The automated scoring was high: BLEU (0.9479), ROUGE-1 (0.969), ROUGE-L (0.9677), fidelity (0.947), answer relevance (0.9587), and context recall rate (0.925). Experts gave highly positive evaluations of the system across all dimensions, indicating its great potential in clinical decision support and patient education, as it can provide safe, professional, fluent, and comprehensive responses. Discussion: MyoATP-AI is a knowledge graph-based question-answering system that integrates GraphRAG and CoT technology for low-concentration atropine control of myopia. It can provide accurate and useful clinical advice, which, on the one hand, can assist doctors in making evidence-based decisions, and on the other hand, can offer reliable and easily understandable medical guidance to patients. Future work will expand the dataset to enhance the system's applicability in different scenarios and help with the prevention and control of myopia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.